.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Healthtrust
Cerilliant
Baxter
US Army
Johnson and Johnson
Daiichi Sankyo
Queensland Health
Deloitte
Boehringer Ingelheim

Generated: June 28, 2017

DrugPatentWatch Database Preview

RELISTOR Drug Profile

« Back to Dashboard

What is the patent landscape for Relistor, and when can generic versions of Relistor launch?

Relistor is a drug marketed by Salix Pharms and Salix Pharms Inc and is included in two NDAs. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has ninety-seven patent family members in thirty-four countries.

The generic ingredient in RELISTOR is methylnaltrexone bromide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.

Summary for Tradename: RELISTOR

Patents:10
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list17
Clinical Trials: see list11
Patent Applications: see list2
Drug Prices:see details
DailyMed Link:RELISTOR at DailyMed

Pharmacology for Tradename: RELISTOR

Ingredient-typeQuaternary Ammonium Compounds
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms
RELISTOR
methylnaltrexone bromide
SOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYesYes9,669,096► SubscribeY ► Subscribe
Salix Pharms
RELISTOR
methylnaltrexone bromide
SOLUTION;SUBCUTANEOUS021964-003Sep 27, 2010RXYesYes8,822,490► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes6,559,158► Subscribe ► Subscribe
Salix Pharms
RELISTOR
methylnaltrexone bromide
SOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYesYes6,559,158► Subscribe ► Subscribe
Salix Pharms
RELISTOR
methylnaltrexone bromide
SOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYesYes8,822,490► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RELISTOR

Drugname Dosage Strength RLD Submissiondate
methylnaltrexone bromideTablets150 mgRelistor9/6/2016
methylnaltrexone bromideInjection8 mg/0.4 mLRelistor9/8/2015
methylnaltrexone bromideInjection12 mg/0.6 mLRelistor7/22/2015

Non-Orange Book Patents for Tradename: RELISTOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,455,644Peripheral opioid receptor antagonists and uses thereof► Subscribe
5,972,954 Use of methylnaltrexone and related compounds► Subscribe
6,608,075 Use of methylnaltrexone and related compounds► Subscribe
9,492,445Peripheral opioid receptor antagonists and uses thereof► Subscribe
6,274,591 Use of methylnaltrexone and related compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RELISTOR

Country Document Number Estimated Expiration
Russian Federation2011117335► Subscribe
Israel211865► Subscribe
Peru00632013► Subscribe
Singapore183133► Subscribe
China102918039► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Healthtrust
Federal Trade Commission
Express Scripts
Cantor Fitzgerald
Moodys
McKesson
Dow
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot